Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jasper Dingemanse
Reply to Letter to the Editor From Asma Akhtar and Ume Hafsa Roman
Dear Editor, We thank Drs Akhtar and Roman for their interest in our article, “Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients with Fabry Disease and Moderate to Severe Renal Function Impairment.”1 Their letter raises three main points: external validation, exposure–response analyses, and heterogeneity between studies.
Multiple‐dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination
Introduction Cenerimod is an orally available and potent sphingosine-1-phosphate receptor 1 (S1P1) modulator, which is a class of drugs that triggers sustained receptor internalization, blocks the egress of lymphocytes from lymphoid organs and, thereby, reduces tissue availability of circulating lymphocytes.1-3 The pharmacodynamic (PD) effect of cenerimod is dose-dependent and sustained with continued once-daily (o.d.) dosing but is reversible upon drug discontinuation.4, 5 Cenerimod is a...
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
1. Introduction 1.1. P2Y12 Receptor Antagonists P2Y12 receptors play a crucial role in platelet aggregation. Early administration of acetylsalicylic acid and a P2Y12 receptor antagonist, i.e., oral dual antiplatelet therapy, is part of the standard of care for acute coronary syndrome (ACS) management [1,2,3]. Approved oral P2Y12 receptor antagonists include clopidogrel, prasugrel, and ticagrelor [4,5,6].
Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Pierre-Eric Juif 1, Markus S. Mueller 1, Hakim Charfi 2 and Jasper Dingemanse 1,* 1 Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland 2 Biotrial, 7–9 Rue Jean-Louis Bertrand, 35000 Rennes, France * Author to whom correspondence should be addressed. Int. J. Mol. Sci.
Effect of the novel dual orexin receptor antagonist daridorexant on night‐time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease
REGULAR RESEARCH PAPER Marie‐Laure Boof Corresponding Author marielaure.boof@idorsia.com orcid.org/0000-0002-6734-5674 Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland Correspondence Marie‐Laure Boof, Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil, Switzerland.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jasper
Contact Jasper, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack